Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Options and Sells Shares

Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on July 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 5, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 6,100 shares of common stock at a price of $8.61 per share.
• Simultaneously, Campbell sold 6,100 shares of common stock at a weighted average price of $10.0048, with prices ranging from $10.00 to $10.02.
• Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 37,500 stock options.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan and do not necessarily indicate a change in the executive's confidence in the company.

Industry Context

Executive stock transactions are common and closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are often used to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Sales of shares acquired through option exercises are a normal part of executive financial planning.
• The use of a Rule 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates